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Abstract
Modern cancer treatment employs many effective chemotherapeutic agents originally discovered 
from natural sources. However, a significant challenge currently confronting clinical application is 
balancing systemic toxicity risk with therapeutic benefit. The cyclic depsipeptide didemnin B has 
demonstrated impressive anti-cancer activity in preclinical models. Clinical use has been approved 
but is limited by sparse patient responses combined with toxicity risk and an unclear mechanism 
of action. From a broad-scale effort to match antineoplastic natural products to their cellular 
activities, we found that didemnin B selectively induces rapid and wholesale apoptosis through 
dual inhibition of PPT1 and EEF1A1. Furthermore, empirical discovery of a small panel of 
exceptional responders to didemnin B allowed generation of a regularized regression model to 
extract a sparse-feature genetic biomarker capable of predicting sensitivity to didemnin B. This 
may facilitate patient selection that could enhance and expand therapeutic application of didemnin 
B against neoplastic disease.
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Introduction
Natural products have contributed substantially to the arsenal of therapeutic compounds in 
use today, most notably as antibiotics and chemotherapy1. Their complex and varied 
chemistries confer potent and diverse bioactivities that have been honed and maintained by 
evolutionary pressure. Identifying the mechanisms of action of bioactive natural products 
has been a major challenge limiting our ability to harness their full therapeutic potential. To 
help address this challenge, we recently assembled a library of marine natural products and 
employed expression signature-based high-throughput screening to map the actions of these 
natural products to genetically-annotated functional space2. This strategy, Functional 
Signature Ontology (FUSION), has been demonstrated to effectively classify natural 
products that modulate a broad range of human cell biological systems, including nutrient 
homeostasis, extracellular matrix signaling, and oncogene signaling2,3.
Here we report the FUSION-inspired characterization of the chemotherapeutic agent 
didemnin B, a depsipeptide isolated from the marine tunicate Trididemnum solidum4,5. 
Didemnin B is of both biological and clinical interest as it targets cancer cell viability in 
vitro and in vivo through a mechanism that is not understood but is clearly distinct from that 
of other known antineoplastic agents6. The chemotherapeutic activity of didemnin B was 
first characterized in leukemia and the analog dehydrodidemnin B has been granted orphan 
drug status for treating acute lymphoblastic leukemia (ALL), though its therapeutic benefit 
does not appear to be limited to hematological malignancies4,6. Clinical trials of didemnin B 
and dehydrodidemnin B have documented responses in patients suffering from a wide array 
of solid tumors, including bronchial carcinoid, colon cancer, esophageal cancer, malignant 
melanoma, medullar thyroid carcinoma, metastatic breast cancer, non-small-cell lung 
cancer, renal cancer, and squamous cell cervical cancer7,8. However, the paucity of 
responders in each of these disease settings has precluded therapeutic application of 
didemnin analogs outside of ALL.
Through identification and characterization of multi-lineage tumor-derived cell lines that are 
exceptional responders to didemnin B, we find that the compound potently induces 
apoptosis, in an identifiable subset of human cancer cell lines, through dual inhibition of 
palmitoyl-protein thioesterase 1 (PPT1) and eukaryotic translation elongation factor 1 alpha 
1 (EEF1A1). Furthermore, we present a quantitative sparse-feature expression biomarker, 
conserved in tumor samples, which can predict exceptional sensitivity to didemnin B in cell 
culture.
RESULTS
Didemnin B activates mTORC1 in vitro and in vivo
As part of a large-scale effort for unbiased mechanism of action annotation of genetic and 
chemical perturbations, we used functional signature-based ontology (FUSION) to cluster 
equivalent biological responses of HCT116 cells to 780 siRNA pools, 344 miRNA mimics, 
and 1186 natural product fractions2. From unsupervised hierarchical clustering2, we 
identified a dense clade heavily populated by reagents known to perturb AKT pathway 
activity (Fig. 1a; AKT2, AKT3, CNKSR19,10, RPS6KB211, WEE112, EEF2K13, miR-714,15, 
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miR-49716,17, miR-38318, the miR-29 family19, and miR-193a20). Natural product fractions 
with FUSION signatures most similar to the genetic perturbations within this clade included 
UT-BA07-004-ETOAC from the tunicate Trididemnum solidum (Fig. 1b), an organism 
known to produce the antineoplastic compound didemnin B4,5. Indeed, structural 
determination revealed the most abundant compound in UT-BA07-004-ETOAC to be 
identical to didemnin B (Supplementary Results, Supplementary Fig. 1a). Guilt by 
association with the FUSION clade predicted activity of didemnin B against AKT pathway 
activation. Consistent with this, a 24-hour exposure of HCT116 cells to this compound 
inhibited AKT signaling in a dose-dependent manner, as indicated by reduced accumulation 
of activation site phosphorylation (S473) on AKT, on its direct substrate TSC2 (T1462), and 
on its downstream effector p70S6K(T389), an mTORC1 substrate (Fig. 1c). However, 
analysis of AKT signaling after short-term didemnin B exposure showed that increased 
phosphorylation of p70S6K (T389) occurred at lower concentrations and earlier time-points 
than any observable inhibition of AKT signaling (Supplementary Fig. 1b, c). Activation of 
mTORC1 is known to engage multiple negative feedback mechanisms that inhibit AKT 
signaling21–24. Indeed, didemnin B induced phosphorylation of the mTORC1 substrate site 
(T389) on p70S6K, with an EC50 of ~100 nM in HCT116 cells (Supplementary Fig. 1c), 
that was completely blocked by the mTORC1 inhibitor rapamycin (Fig. 1d). The mTORC1 
substrate sites (T37/46) on 4E-BP1 responded similarly (Supplementary Fig. 1d). Activation 
of mTORC1 by didemnin B was conserved in all cell lines tested, including HCT116, 
U2OS, HeLa, primary human fibroblasts, telomerase-immortalized colonic epithelial cells, 
and mouse embryonic fibroblasts (Fig. 1d and Supplementary Fig. 1) as well as Vaco451 
(see below). Importantly, intraperitoneal injection of didemnin B in mice induced a dose-
dependent activation of mTORC1 in the liver, recapitulating the observations in tissue 
culture cells (Supplementary Fig. 1h).
Didemnin B activates mTORC1 by inhibition of Redd-1
Two direct protein targets of didemnin B have been identified: the eukaryotic translation 
elongation factor 1 alpha 1 (EEF1A1)25 and the palmitoyl-protein thioesterase 1 (PPT1)26. 
Didemnin B can inhibit protein translation by binding EEF1A1 and stabilizing aminoacyl-
tRNA bound to the ribosomal A-site, thus preventing translocation27. Didemnin B is also a 
noncompetitive inhibitor of PPT1-dependent degradation of palmitoylated proteins in 
lysosomes28. To determine if didemnin B activity on the mTOR pathway could be ascribed 
to one of these known targets, we first examined if distinct chemical inhibitors of protein 
synthesis or PPT1 were sufficient to activate mTORC1. U2OS cells cultured under low 
nutrient conditions, to reduce basal mTORC1-S6K-S6 activity, were treated with 
cycloheximide (10 μg/ml) or puromycin (10 μg/ml) for 30 minutes. Both inhibitors of 
protein synthesis activated mTORC1 as indicated by increased phosphorylation of S6K and 
S6, while the PPT1 inhibitor HDSF29 did not (Supplementary Fig. 1i, j). In parallel assays, 
the extent of co-administered low-dose puromycin incorporation into nascent polypeptides 
was used as an indicator of protein synthesis, and confirmed translational inhibition by 
didemnin B (1 μM or 1.11 μg/ml) and cycloheximide (10 μg/ml) (Supplementary Fig. 1k). In 
contrast, hygromycin B, which impairs fidelity of translation without altering the rate of 
protein synthesis, neither activated mTORC1 nor impaired puromycin incorporation 
(Supplementary Fig. 1i, k). As expected, inhibition of protein synthesis was also 
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accompanied by loss of the short-lived protein p53 (Supplementary Fig. 1k). Biological 
consequences of mTORC1 activation with either didemnin B or cycloheximide could be 
detected by accumulation of S6K phosphorylation within five minutes, accumulation of S6 
phosphorylation within 10 minutes, and decreased autophagolysosome maturation within 
120 minutes (Fig. 1e). Collectively, these observations indicate that translational inhibition 
activates mTORC1 and associated downstream signaling in a manner that is rapid, broad, 
and sustained. We considered that the mechanism underpinning the mTORC1 response to 
translational suppression might be accumulation of free amino acids and/or loss of a short-
lived negative regulator30–32. Translational inhibition activated mTORC1 whether free 
amino acids were abundant (Fig. 1d and Supplementary Fig. 1b–h) or removed from the 
media (Fig. 1e, f and Supplementary Fig. 1i, l–n). However, among mTORC1 regulatory 
proteins, we found that loss of the mTORC1-inhibitor REDD1 strongly correlated with 
mTORC1-S6K-S6 activation induced by both cycloheximide and didemnin B (Fig. 1e and 
Supplementary Fig. 1l). Importantly, REDD1 knockout MEFs responded to amino acids by 
activation of mTORC1 signaling, but failed to respond to didemnin B or cycloheximide 
(Fig. 1f and Supplementary Fig. 1m, n). These findings indicate that REDD1 expression is 
required to couple mTORC1 activation to protein translation activity and that didemnin B 
activates mTORC1 through the same mechanism as cycloheximide (Supplementary Fig. 
1o)30–32.
Selective induction of apoptosis by didemnin B
Although didemnin B and synthetic analogs have entered clinical trials for several 
oncological diseases, the anti-cancer mechanism of action is not yet understood6. Therefore 
we wished to test whether translational inhibition and mTORC1 activation contribute to the 
ability of didemnin B to induce cancer cell death. Among a small panel of breast cancer and 
colon cancer cell lines tested, we observed exceptionally selective toxicity in the colon 
cancer cell line Vaco451 (Fig. 2a, b and Supplementary Fig. 2a, b). Didemnin B toxicity in 
this colon cancer cell line achieved 100% kill at concentrations of 247 nM or higher within 
96 hours of treatment, and displayed an LC50 of ~32 nM (Supplementary Fig. 2a) with no 
consequence on telomerase-immortalized colonic epithelial cells, HCT116 colon cancer 
cells, or any of several additional tumor-derived cell lines tested (Fig. 2a–c and 
Supplementary Fig. 2a, b). Remarkable selectivity for Vaco451 cells was observed at 
multiple time-points (ranging from 4–96 hours) and concentrations (ranging from 0.08 – 60 
μM) of didemnin B treatment (Fig. 2a–c and Supplementary Fig. 2a, b). A four-hour 
exposure to didemnin B at concentrations of 247 nM or higher was sufficient to kill >90% of 
Vaco451 cells, without any reduction in viability of resistant cell lines at any concentration 
tested, up to 60 μM (Fig. 2b). The mode of cell death was apoptosis, with maximal induction 
of caspase activity observed within two hours of treatment in the exceptionally sensitive cell 
line (Fig. 2c, d).
Didemnin B targets PPT1 and EEF1A1 to induce apoptosis
Notably, cell death was not rescued by pretreatment with rapamycin or Torin, indicating that 
activation of mTORC1 by didemnin B is not required for induction of cell death in Vaco451 
cells (Supplementary Fig. 2c–h). Furthermore, although cycloheximide (10 μg/ml) inhibited 
protein synthesis in Vaco451 cells slightly better than didemnin B (1 μM or 1.11 μg/ml), it 
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displayed minimal caspase activation in comparison to didemnin B (Supplementary Fig. 3a–
c). Concordantly, translational inhibition via cycloheximide at this dose was insufficient to 
kill Vaco451 cells (Supplementary Fig. 3d). Concentrations of cycloheximide as high as 30 
μg/ml (106.6 μM) were required to obtain modest reductions in cell viability (Supplementary 
Fig. 3e). These observations demonstrate that translational inhibition is insufficient to 
account for the remarkable response of Vaco451 cells to didemnin B, and indicate the 
participation of additional protein targets.
The didemnin B target enzyme palmitoyl-protein thioesterase 1 (PPT1)26,28 is considered 
generally dispensable for cell viability and function, as PPT1 knockout mice develop 
normally and remain healthy until neurodegeneration manifests with age33. However, 
selective vulnerability to PPT1 inhibition within tumorigenic regulatory contexts has not 
been examined. Transfection of a pool of siRNA oligos targeting PPT1 reduced PPT1 
protein expression in Vaco451 cells below the limit of detection by western blot analysis 
(Supplementary Fig. 3f), but no consequences on cell viability were detected (Fig. 3a). 
However, siRNA-mediated depletion of PPT1 selectively sensitized Vaco451 cells to 
cycloheximide (Fig. 3a and Supplementary Fig. 3g). Four of five independent siRNA oligos 
targeting PPT1 were effective, arguing against the interpretation that sensitization was due 
to an off-target effect of the reagents employed (Supplementary Fig. 3f, h). Furthermore, an 
independent siRNA pool targeting PPT1 also sensitized to cycloheximide, as did three of 
four individual oligos within the second pool (Supplementary Fig. 3i, j). The sensitization 
was specific for PPT1 and was not observed with siRNAs targeting PPT2 (Supplementary 
Fig. 3i). We also did not observe sensitization to other potential inducers of apoptosis such 
as Smac mimetic or CFLAR RNAi upon PPT1 depletion (Fig. 3a and Supplementary Fig. 
3k). Since PPT1 is a lysosomal thioesterase with optimal activity at pH of 4.034, we asked 
whether inhibition of lysosomal acidification via the vacuolar-ATPase inhibitor bafilomycin 
A1 would also sensitize Vaco451 cells to translational inhibition. Indeed, pretreatment with 
50 nM bafilomycin A1 for 30 minutes sensitized to 10 μg/ml cycloheximide, resulting in 
>50% cell death after six hours (Fig. 3b). Sensitivity to combinatorial treatment with 
inhibitors of the vacuolar ATPase and protein synthesis was detected specifically in the 
didemnin B sensitive cell line Vaco451, but not didemnin B resistant cell lines Vaco866 or 
HCT116 even up to concentrations of 100 μg/ml cycloheximide and 200 nM bafilomycin A1 
(Fig. 3b and Supplementary Fig. 3l, m). Rapamycin was not capable of substituting for 
cycloheximide in the combinatorial treatment, likely because it only inhibits translation of a 
specific subset of mRNAs, unlike cycloheximide, which broadly inhibits protein synthesis32 
(Supplementary Fig. 3n). Finally, the PPT1 inhibitor hexadecylsulfonylfluoride (HDSF)29 
selectively sensitized Vaco451, but not HCT116, to translational inhibition (Fig. 3c, d). 
Taken together, these observations indicate that didemnin B kills exceptional responders 
through combinatorial inhibition of PPT1 and protein synthesis.
Mcl-1 accumulation is sensitive to EEF1A1 inhibition
We next tested whether translational inhibition might contribute to didemnin B-induced 
apoptosis in Vaco451 cells through depletion of one or more short-lived anti-apoptotic 
proteins such as Mcl-1 or c-Flip (encoded by the CFLAR gene). We first surveyed the effect 
of translational inhibition in Vaco451 cells on a handful of apoptosis-modulating proteins 
Potts et al. Page 5
Nat Chem Biol. Author manuscript; available in PMC 2015 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
known to be rapidly degraded in other contexts (Supplementary Fig. 3n). We found that 
Mcl-1 and c-Myc were easily detected at baseline but disappeared rapidly upon translational 
inhibition in these cells, in a proteasome-dependent manner, with kinetics similar to those of 
caspase activation by didemnin B (Fig. 3e, Fig. 2d, and Supplementary Fig. 3n). On the 
other hand, c-Flip was barely detectable and disappeared with slightly slower kinetics 
(Supplementary Fig. 3o). Notably, didemnin B-induced cell death required proteasome 
function, as pretreatment with the proteasome inhibitor MG132 completely rescued viability 
in didemnin B-treated Vaco451 cells (Fig. 3f). This suggested that degradation of one or 
more proteasome substrates may be required for induction of apoptosis by didemnin B. 
Depletion of c-Flip using siRNA targeting CFLAR had no effect on viability of Vaco451 
cells alone or in combination with PPT1 siRNA (Supplementary Fig. 3k). Depletion of c-
Myc reduced viability by about half in Vaco451 cells, likely due to decreased proliferation, 
but did not sensitize to PPT1 siRNA (Supplementary Fig. 3p). Furthermore, neither gain nor 
loss of function of c-Myc modulated didemnin B-induced cell death (Supplementary Fig. 3q, 
r)35. In contrast, the Mcl-1 inhibitor TW-37 induced caspase activation and massive cell 
death selectively in Vaco451, but not HCT116 or Vaco866, pre-treated with the PPT1 
inhibitor HDSF (Fig. 3g and Supplementary Fig. 3s–u). Together, these data suggest that 
didemnin B induces apoptosis in Vaco451 cells by combinatorial depletion of Mcl-1 and 
inhibition of PPT1.
Rare and diverse representation of didemnin B sensitivity
To develop leads for molecular contexts that may account for or correlate with exceptional 
response to didemnin B, we searched for additional sensitive cell lines. From NCI-60 
profiling efforts, the acute promyelocitic leukemia cell line HL-60 was found to undergo 
rapid and complete apoptosis in response to 1 μM didemnin B exposure36. One commonality 
between the colorectal cancer cell line Vaco451 and the acute promyelocitic leukemia cell 
line HL-60 is substantial amplification of the Myc locus37,38. This led us to test whether 
Myc amplification might predict sensitivity to didemnin B within a small panel of cancer 
cell lines of known Myc copy number status39 (Supplementary Fig. 4a). However, we found 
no association between Myc amplification status and sensitivity to didemnin B among this 
panel (Supplementary Fig. 4a). While these efforts eliminated Myc amplification as a 
predictive marker, they successfully uncovered two additional didemnin B sensitive cell 
lines: the breast cancer cell line HCC1187 and the small cell lung cancer cell line NCIH211 
(Supplementary Fig. 4a). Among the cell line panel tested, selective sensitivity of HCC1187 
and NCIH211 was observed at concentrations of didemnin B ranging from 0.08–60 μM and 
treatment times ranging from 4–72 hours (Fig. 4a and Supplementary Fig. 4b, c). Like 
Vaco451, both HCC1187 and NCIH211 responded to didemnin B with rapid activation of 
caspases (Fig. 4b and Supplementary Fig. 4d), were resistant to single agent administration 
of cycloheximide (Supplementary Fig. 4e), and were selectively sensitive to siRNA-
mediated co-depletion of PPT1 and Mcl-1 (Fig. 4c). These observations suggest that a subset 
of epithelially-derived human cancer cells spanning multiple tissues of origin exhibit 
selective sensitivity to didemnin B-induced apoptotic cell death through the same 
mechanism of action.
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Multi-feature biomarker predicts didemnin B sensitivity
We therefore leveraged this cohort to generate a data-driven molecular response predictor 
using the elastic net penalized linear regression model40. Genome-wide mRNA expression 
data obtained using a common technical platform is publicly available from three of the four 
sensitive lines, as well as ten of the cell lines we found to be resistant to didemnin B (Fig. 
2b, c, Fig. 4a and Supplementary Fig. 4a). From a binary indication of “sensitive” or 
“resistant” assigned to each cell line, a four-gene biomarker emerged, such that high 
expression of LOC101927886, HNRNPM, BCL11A, and TP53BP2 correlated with 
sensitivity to didemnin B among the 13 cell lines (Fig. 5a). This multi-feature biomarker 
was used to predict sensitivity among 1022 additional cell lines for which microarray data 
were available (Fig. 5b and Supplementary Data Set 1). Normalized predictive values 
ranged from 0.141 (predicted to be most sensitive) to −0.080 (predicted to be most resistant). 
Cancer cell lines from the “haematopoietic and lymphoid tissue” lineage were highly 
enriched among top-ranked predicted sensitive lines (indicated in purple in Fig. 5b and 
Supplementary Data Set 1). Cell lines derived from patients with ALL were particularly 
enriched among top-ranked lines, which is notable given that a synthetic analog of didemnin 
B has been granted orphan drug status in this disease setting (Supplementary Data Set 1)6. 
Of note, rare cell lines from other lineages such as “breast” (yellow) and “lung” (blue) were 
also among top-ranked predicted sensitive lines (Fig. 5b and Supplementary Data Set 1). To 
ask whether this was an artifact of cell culture or, alternatively, might indicate the presence 
of a rare, distinct subset of epithelially-derived cancer patients, we applied the multi-feature 
biomarker to publicly available expression profiles from patient-derived tumor samples 
assembled by The Cancer Genome Atlas (http://cancergenome.nih.gov/). Indeed, patient-
derived tumor samples spanned a larger range of predicted sensitivity than that represented 
by the cell line panel, with three colorectal adenocarcinoma patient samples in particular 
displaying a stronger match to the multi-feature biomarker predicting sensitivity to didemnin 
B than any cell line in the panel (Supplementary Data Set 2, Fig. 5c, and Supplementary Fig. 
5a, b). To evaluate the predictive potential of the multi-feature biomarker among 
epithelially-derived cancers, five non-hematopoietic lines spanning the entire range were 
obtained and tested for sensitivity to didemnin B (Fig. 5d, e). The breast cancer cell line 
HCC1599, ranked # 13 of 1022, had the highest predicted sensitivity among cell lines to 
which we had access, and was indeed a remarkable responder to didemnin B (Fig. 5d, e and 
Supplementary Fig. 5c–e). The lung cancer cell line NCIH82, ranked # 35 of 1022, 
displayed partial sensitivity that required either higher concentrations of didemnin B or 
longer treatment times to exhibit responses comparable to those seen with fully sensitive 
lines (Fig. 5d, e and Supplementary Fig. 5c–e). The remaining cell lines tested, ranked # 
192, # 337, and # 1022 of 1022, were all resistant to didemnin B (Fig. 5d, e and 
Supplementary Fig. 5c–e). Thus the multi-feature biomarker could successfully predict 
sensitivity to didemnin B among epithelially-derived human cancer cell lines propagated in 
culture and could identify a subset of colorectal, breast, and lung cancer patients that might 
be expected to respond to didemnin B or its analogs.
GSEA further indicates polypharmacology of mechanism
A total of four sensitive lines and ten resistant lines with associated expression data were 
used in an S2N analysis to identify the top 2% of differentially expressed genes between 
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didemnin B-sensitive and -resistant classes (Fig. 6a, Supplementary Fig. 6a and 
Supplementary Data Set 3). Pathway enrichment analysis identified “KEGG_LYSOSOME” 
as one of the top pathways enriched in the resistant versus sensitive class (p=0.0014, 
hypergeometric test, Supplementary Data Set 4). The leading-edge genes included CLN5, 
which similarly to the didemnin B target PPT1 (also called CLN1), is mutated in some 
forms of neuronal ceroid lipofuscinoses41 (Fig. 6b, Supplementary Data Sets 3 and 4). 
Conversely, the top pathway enriched in the sensitive versus resistant class was 
“1060_Retromer complex (SNX1 SNX2 VPS35 VPS29 VPS26B)” with p=0.0010 by the 
hypergeometric test (Supplementary Data Set 5). Given that CLN5 is required for 
recruitment of the retromer to the lysosomal sorting receptor42, these findings suggest a 
coherent biological process which may be impaired specifically in the didemnin B sensitive 
class of cancer cells. In addition, EEF1A2, which is 98% similar (92% identical) to the 
didemnin B target EEF1A1 and functions similarly in translational elongation43, was one of 
the top 2% of genes expressed more highly in the resistant than the sensitive class by S2N 
analysis (Fig. 6c and Supplementary Data Set 3).
Biomarker enrichment in hematologic cancers
Although 12 of the 13 cell lines used to generate the multi-feature biomarker were derived 
from solid tumors of epithelial origin, CCLE lines predicted to be sensitive to didemnin B 
were highly enriched for those from hematopoietic lineages (Fig. 5a, b, Supplementary Data 
Set 1, and discussed above). Analysis of biomarker-derived sensitivity scores among several 
leukemia and lymphoma patient cohorts exhibited a wide range of predicted sensitivity 
(Supplementary Fig. 6b). Therefore, we acquired eight hematopoietic lines from the CCLE 
panel that spanned the range of predicted sensitivity and tested the ability of didemnin B to 
induce apoptosis. Three of four predicted responders were indeed sensitive to didemnin B by 
this criterion (Supplementary Fig. 6c). Sensitive lines from the hematopoietic lineages 
responded to didemnin B by rapid apoptotic cell death that was similar with respect to 
magnitude (<5% viability), active dose range (0.02 – 60 μM) and timing/persistence (4 – 72 
hours) to that of sensitive lines from epithelial lineages (Fig. 6d and Supplementary Fig. 6d, 
e).
DISCUSSION
Using quantitative gene expression signatures as a pattern-matching tool for detection of 
mechanistically equivalent chemical and genetic perturbations, the cyclic depsipeptide 
didemnin B was identified as a persistent mTORC1 pathway agonist in vitro and in vivo. 
Mode of action studies indicated this activity was the consequence of release of REDD1-
dependent inhibition of mTORC1 via the well-described suppression of protein translation 
by didemnin B. These observations revealed REDD1 as a short-lived protein that acts as a 
self-sufficient brake on latent mTORC1 activity. Loss of REDD1 accumulation resulted in 
rapid and full mTORC1 activation in the absence of instructive signals such as amino acids, 
growth factors, or serum. This relationship suggests that, within the complex hierarchy of 
mTORC1 pathway control mechanisms, coupling of mTORC1 activity to dynamic rates of 
protein synthesis is dominant to signal transduction mechanisms that monitor nutrient 
availability or mitogen pathway activity.
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REDD1-mediated mTORC1 inhibition therefore likely serves to maintain equilibrium 
between cellular rates of protein synthesis and degradation across ever-changing conditions. 
The robustness of this system is perhaps highlighted by the fact that humans can develop 
and thrive even when protein synthesis is substantially perturbed by mutations in genes 
encoding core translational machinery. Notably, a sequela of such genetic diseases, termed 
ribosomopathies, is an increased incidence of cancer44. This could be due to sustained 
activation of mTORC1 in response to impaired protein translation through the mechanism 
described here.
Didemnin B has long been recognized as an antiproliferative agent, in a variety of 
inflammatory and neoplastic settings, with a cryptic mechanism of action that is not 
accounted for by targeting EEF1A18. From a cohort of molecularly characterized breast, 
colon, and lung tumor-derived cell lines, we identified exceptional responders to didemnin 
B-induced apoptosis. Mechanistic evaluation of this activity indicated an obligate 
combinatorial suppression of both protein targets of didemnin B, EEF1A125,27 and 
PPT126,28. This adds didemnin B to a growing list of anti-neoplastic compounds in which 
the bioactivity of interest results from plural mechanisms of action of a single molecule.
We found that didemnin B causes rapid loss of the anti-apoptotic protein Mcl-1, and that 
selective induction of apoptosis in sensitive cancer cell lines by didemnin B could be 
reproduced by combinatorial treatment with the PPT1 inhibitor HDSF and the Mcl-1 
inhibitor TW-37. This mechanistic insight raises two distinct therapeutic possibilities 
warranting further investigation. First, in clinical settings where didemnin B analogs are 
found to be effective, combinatorial treatment with specific inhibitors of PPT1 and Mcl-1 
might potentially maintain effectiveness while reducing toxicity otherwise caused by blunt 
translational inhibition7,45. Second, in clinical settings where Mcl-1 represents a resistance 
mechanism to an otherwise promising therapeutic option (or a bona fide target itself), 
didemnin B analogs may be effective in combination with other therapies (or as a single 
agent)46,47.
Public efforts facilitating accumulation of molecular annotations for both tumor-derived cell 
lines and tumor tissues allowed identification of conserved genomic features that predict 
exceptional response to didemnin B. Specifically, a multi-feature quantitative gene 
expression profile was sufficient to predict tumor-derived cell lines with an apoptotic 
response to low-dose didemnin B. By ranking the diverse human cancer cell lines 
represented in the CCLE, we noted a significant enrichment of hematological malignancies 
as compared to other disease lineages. This is notable given that dehydrodidemnin B was 
granted orphan drug status for treating ALL and is currently in phase 1, 2, and 3 clinical 
trials for other hematological malignancies. When applied to patient cohorts across multiple 
solid tumor disease settings, this biomarker identifies a distinct population of patients that 
we believe may be most likely to respond to didemnin B or its analogs. Though genome-
wide expression data are not routinely used diagnostically, this biomarker may correlate 
with more easily detected features such as translocations. Intriguingly, both breast cancer 
cell lines identified as sensitive to didemnin B in this study (HCC1187 and HCC1599) 
harbor activating Notch rearrangements, a relatively rare event in this disease setting48. 
Furthermore, predicted sensitivity to didemnin B positively correlated with presence of the 
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TEL-AML fusion in two independent preB-ALL patient cohorts (GSE12995, p=1.1e-05, and 
GSE13425, p=7.3e-08). If verified by clinical studies assessing patient outcome, these 
biomarkers could enable guided therapeutic use of didemnin B or an analog in patients most 
likely to respond, thus expanding the clinical benefit without unnecessarily exposing large 
numbers of patients to the associated toxicities.
ONLINE METHODS
Cell lines
Cell lines are as described49–51. They were kind gifts from Adi Gazdar (breast cancer lines), 
James Willson and Sandy Markowitz (Vaco colon cancer lines), Jerry Shay (human colonic 
epithelial cells), John Minna (lung cancer lines), Fred Grinnell (BR5 human fibroblasts), 
Ryan Potts (U2OS), Xiaodong Wang (U2OS GFP-LC3 and Jurkat), Josh Mendell (P493), 
and James Brugarolas (REDD1 wild-type and knockout MEFs), or were purchased from the 
ATCC (HCT116) or the DSMZ (TALL-1 and RCH-ACV). The identities of all human 
cancer cell lines from epithelial origin were verified using the Promega Powerplex 1.2 
system and an in-house database of more than 500 reference fingerprints52. Growth media 
was DMEM supplemented with 10% fetal bovine serum (FBS) for HCT116, U2OS, HeLa, 
MEF, and BR5 fibroblast cells. Growth media was MEM2+ for Vaco576 and Vaco871 cells. 
Growth media was Iscove’s supplemented with 20% FBS for OCI-M1, OCI-Ly3, OCI-
Ly10, and OCI-Ly19. Growth media was AlphaMEM supplemented with 10% FBS for 
OCI-AML3. Growth media was RPMI supplemented with 5–15% FBS (as directed by 
supplier) for all remaining cell lines, except for the normal human colonic epithelial cells 
(HCECs), which were maintained and passaged in S+2% media under low oxygen 
conditions, but were assayed in RPMI supplemented with 10% FBS under normoxia 
conditions. The U2OS cell line stably expressing GFP-LC3 was used to assess the effect of 
translational inhibition via didemnin B or cycloheximide on autophagy53.
Antibodies and other materials
Antibodies recognizing pan-AKT, p-AKT (S473), GSK3β, p-GSK3β (S9), TSC2, p-TSC2 
(T1462), S6K, p-S6K (T389), S6, p-S6 (S235/6), PRAS40, ULK1, Rag A, Rag B, Rag C, 
AMPK, cleaved PARP, and Mcl-1 were from Cell Signaling Technology. β-tubulin antibody 
was from Sigma-Aldrich. XPB (TFIIH p89 S-19), p53, c-Myc, and GFP antibodies were 
from Santa Cruz. Puromycin antibody was from KeraFAST. REDD1/DDIT4 antibodies 
were from Novus and Bethyl. C-FLIP antibody was from Enzo Life Sciences. All antibodies 
were used at final concentrations of 1:1000 – 1:2000 except for cleaved PARP, c-Myc, p-
TSC2, ULK1, and XPB (1:500), AMPK, P70S6K, and TSC2 (1:750), and β-tubulin, S6, and 
p-S6 (1:4000). DMSO, cycloheximide, puromycin, rapamycin, bafilomycin A1, and 
MG-132 were from Sigma-Aldrich. Hygromycin B was from Corning. 
Hexadecylsulfonylfluoride (HDSF) was from Santa Cruz. TW-37 was from Selleckchem. 
Torin1 was a kind gift from David Sabatini and Nathanael Gray. Smac mimetic was a kind 
gift from Xiaodong Wang.
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Natural products
Generation and functional mapping of the natural product library was described previously2. 
Tunicate sample UTSW-BA07-004 was collected at Sweetings Cay, Bahamas in 2008. 
Based on morphology, the tunicate was identified as Trididemnum solidum. A type sample is 
preserved in the MacMillan lab at UTSW. An additional Trididemnum solidum specimen 
was kindly provided by Tadeusz F. Molinski (UC – San Diego). A sample of T. solidum (60 
g wet wt.) was lyophilized, extracted with CH2Cl2:MeOH (2:1) for 24 hours and 
concentrated. Subsequent partitioning between aq. MeOH (10%) and n-hexane, aq. MeOH 
(30%) and CH2Cl2. Didemnin B was found to be present in large quantities in the CH2Cl2 
fraction, which was subsequently purified using flash SiO2 chromatography with a gradient 
of CH2Cl2:MeOH (100:0 to 80:20) to give UTBA07-didemnin B (10 mg). Didemnin B, 
white solid, [α]D25 −81.4 (c 0.5, CH2Cl2); 1H NMR (Supplementary Fig. 1a, 500 MHz, 
CDCl3) and 13C NMR (125 MHz, CD3Cl3) are consistent with previously reported NMR 
data54; HRESIMS [M + H]+m/z 1112.6492 (calcd for C57H90N7O15, 1112.6495).
Compound treatment, viability assays, caspase activity assays, and western blots
Cells were plated in 96-well plates for viability assays and caspase activity assays, and in 
96-, 24-, 12-, or 6-well plates for lysate collection for western blot experiments. Compounds 
in DMSO were added to achieve the indicated final concentration, for the indicated length of 
time. The same volume of DMSO was added as a negative control. Viability was measured 
using CellTiter Glo (Promega) following the manufacturer’s protocols, or caspase activity 
was measured using Caspase-Glo reagent (Promega) following manufacturer’s protocols, or 
cells were collected in hot 2x sample buffer, boiled, and sonicated for immunoblot analysis 
using standard western blot protocols. XPB (TFIIH p89 S-19, Santa Cruz) was used as a 
loading control.
Mice
Didemnin B was formulated in 90% D5W + 5% cremophor + 5% DMSO for animal 
delivery. Three female SCID-NOD mice per condition (6–8 weeks of age) were treated with 
high concentration didemnin B (1 mg/kg), low concentration didemnin B (0.11 mg/kg) or 
vehicle alone, by two intraperitoneal injections 96 hours and 7 hours before harvesting livers 
for flash freezing in liquid nitrogen. Lysates were generated from small sections of mouse 
liver in M-PER Mammalian Protein Extraction Reagent (Thermo Scientific) supplemented 
with Phosphatase Inhibitor Cocktails #2 and #3 (Sigma-Aldrich) using a TissueLyser II 
(Qiagen), following the manufacturer’s protocols. 10–40 μg per sample was loaded on each 
of four SDS-PAGE gels and analyzed by standard western blot protocols. These animals 
were cared for according to guidelines set forth by the American Association for 
Accreditation of Laboratory Animal Care and the U.S. Public Health Service policy on 
Human Care and Use of Laboratory Animals. All mouse studies were approved and 
supervised by the UT Southwestern Institutional Animal Care and Use Committee.
Puromycin incorporation assay
Cells were plated in 6-well plates and pre-treated with the indicated compounds at the 
indicated concentrations for 30 minutes. Puromycin (Sigma-Aldrich) was added to the 
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media at a final concentration of 1 μM (0.471 μg/ml). Thirty minutes after addition of 
puromycin, cells were pelleted, resuspended in hot 2X sample buffer, boiled, sonicated, and 
loaded on a 5–15% SDS-PAGE gel (Bio-Rad). After transfer to PVDF membrane, standard 
western blot protocols were used to probe with the antibody recognizing puromycin 
(KeraFAST) and other indicated antibodies.
Amino acid stimulation
Cells were plated in 6-well plates in growth media. Two days later, media was removed, 
cells were rinsed once with EBSS, and fresh EBSS was added. Two hours later, L-glutamine 
was added to a final concentration of 2 mM only in wells destined for amino acid 
stimulation. One hour later, amino acids were added to a final concentration of 1x for the 30 
minute time-point. Twenty minutes later, amino acids were added to a final concentration of 
1x for the 10 minute time-point. Ten minutes later, lysates were collected and analyzed by 
western blot.
RNA interference
RNAi was performed by transfecting siRNA oligos via reverse transfection using RNAiMax 
(Life Technologies) according to the manufacturer’s instructions. 96-well plate format was 
used. A pool of four siRNA oligos targeting each gene was used to dilute off-target effects, 
except where use of an individual siRNA oligo was specifically indicated. Pools of four 
siRNAs targeting either LONRF1 or UBB were used as negative or positive transfection 
controls, respectively.
Elastic net for predictive biomarker discovery
The elastic net is a penalized linear regression model that is used to select features that are 
associated with a drug response, measured, in this case, as a binary vector of sensitivity. The 
elastic net is member of a class of machine learning procedures that are specialized for the 
case when there are many more input features (i.e. gene expression measurements) than 
samples (i.e. cancer cell lines or tissues). It is advantageous in that it allows for the 
identification of multi-feature biomarker signatures whose additive patterns across the cell 
line panel act to predict a response vector. The elastic net also allows for the weighting of 
identified features to enable predictions of sensitivities in untested cell lines. We specifically 
chose the elastic net because it combines the advantages of an L1-norm (Lasso) regression 
and an L2-norm (Ridge) regression model. Candidate predictive features were selected from 
21,087 measures of copy number expression profiles from Affymetrix SNP 6.0 arrays, 
14,569 measures of gene expression from Affymetrix Human Genome U133 Plus 2.0 
microarray platforms, and 1,667 measures of binary mutation statuses from massively 
parallel sequencing across 13 cell lines. Normalized values for each dataset were 
downloaded from the CCLE website (http://www.broadinstitute.org/ccle/), and duplicated 
measurements for the same gene were compressed into a single value by taking the median 
value between the duplicates.
Let X ∈ ℝnxp be the matrix of predictive features where n is the number of cell lines 
included in the training dataset and p is the number of features, and let y ∈ ℝn be the vector 
of binary sensitivity values for the same cell line panel. Columns of the predictive features 
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matrix and y were normalized to have a mean of zero and a standard deviation of 1. The 
elastic net attempts to find which weighted linear combination of the columns of the 
predictive features matrix can best approximate y, or it solves the following equation for w:
The elastic net solves the above by enforcing a penalty to the solution that makes the 
solution both unique and sparse so that only the features that best approximate y are left with 
non-zero weight values. It does this by combining L1-norm and L2-norm regularization 
parameters so that the elastic net formulation to the above problem is given by:
where λ, α, are two adjustable parameters such that λ controls the degree of the overall 
penalty and α controls the degree to which the L1 norm and L2 norm constraints are applied 
so that when α=0, only the L1 penalty is applied and when α=1, only the L2 penalty is 
applied. In order to determine the optimal values of alpha and lambda to use in the model, 
we did 100 iterations of 5 fold cross-validation where, in each iteration, the cells were 
randomly re-sampled into different groups. The values of alpha and lambda were chosen to 
be those that resulted in the minimum mean squared error for each fold. Features were then 
chosen to be those with the highest weights that were selected as features in at least 70% of 
the cross-validation permutations.
Predicting sensitivities in untested cell lines
Weights were calculated for each of the features selected from the elastic net using the 
original 13 cell lines as a training set. Normalized predictive sensitivity values for untested 
cell lines were then calculated for each of the 1022 cell lines in the cancer cell line 
encyclopedia that were not included in the original training set with the following formula:
where wi is the weight determined from the elastic net for feature i, and xij is the normalized 
expression value of feature i in cell line j. The range of si values predicts the degree of 
sensitivity where a high value of si predicts sensitive and a low value of si predicts 
resistance. The described four feature gene signature was used to predict sensitivities in cells 
from the CCLE panel. The probe for ‘LOC101927886’ was not present in the tumor 
datasets, so a three feature gene signature was used to predict tumor sensitivities.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Natural product FuSiOn identifies didemnin B as an activator of mTORC1
(a) The FUSION clade enriched for known AKT pathway elements. Protein-coding genes 
and microRNAs known to participate in AKT signaling are highlighted in blue. ALDOC, 
aldolase C; NDRG1, N-myc downstream regulated 1; BNIP3L, BCL2/adenovirus E1B 
19kDa interacting protein 3-like; BNIP3, BCL2/adenovirus E1B 19kDa interacting protein 
3; ACSL5, acyl-CoA synthetase long-chain family member 5; LOXL2, lysyl oxidase-like 2. 
(b) The Euclidean rank sum values of the top 50 miRNA mimics and siRNA pools (of 1124 
total) whose functional signatures correlate with that produced by UT-BA07-004-ETOAC 
are shown in rank order. Values corresponding to reagents from the AKT clade, shown in 
(a), are labeled. (c) 24 hour treatment of HCT116 cells with didemnin B inhibits AKT 
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signaling. (d) 2.5 hour treatment of HCT116 cells with didemnin B activates P70S6K in a 
rapamycin-sensitive manner. (e) Didemnin B induces Redd-1 loss. (f) Didemnin B fails to 
activate mTORC1 in REDD1 knockout MEFs (REDD1 −/−). All immunoblots (c, d, e, f) are 
representative of two or more experiments.
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Figure 2. An exceptional responder reveals context-specific induction of apoptosis by didemnin B
(a) Didemnin B is selectively toxic in Vaco451 vs. HCEC. Indicated cell lines were treated 
with 1 μM didemnin B or equivalent volume DMSO for five hours before cells were 
imaged. Scale bar = 0.05 mm. (b) Vaco451 responds to low-nM concentrations of didemnin 
B. The indicated cell lines were treated with didemnin B at the indicated concentrations for 
six hours before cell viability was measured. Mean +/− SEM of triplicates is shown. (c) 
Didemnin B selectively induces apoptosis in Vaco451 cells. Indicated cell lines were treated 
with didemnin B at the indicated concentrations for three hours before caspase activity was 
measured. Mean +/− SEM of triplicates is shown. Legend from (b) applies also to (c). (d) 
Maximal caspase activation occurs within 2 hours of didemnin B exposure. Vaco451 cells 
were treated with 1 μM didemnin B or DMSO alone for the indicated time period before 
caspase activity was measured. Mean +/− SEM of triplicates is shown.
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Figure 3. Combinatorial inhibition of PPT1 and protein synthesis recapitulates selective 
induction of apoptosis by didemnin B
(a) PPT1 RNAi sensitizes Vaco451 cells to translational inhibition. 72 hours post-
transfection, cells were exposed to the indicated compounds for 6 hours. Mean + SEM of 
triplicates is shown. (b) Bafilomycin A1 sensitizes Vaco451 cells to translational inhibition. 
Indicated cells were pretreated with DMSO or 50 nM Bafilomycin A1 for 30 minutes before 
addition of DMSO, 10 μg/ml cycloheximide, or 1 μM didemnin B. Mean + SD of triplicates 
is shown. ns, p > 0.05; **, 0.001 < p < 0.01 by unpaired t test. (c) 24-hour pretreatment with 
HDSF sensitizes Vaco451 cells to caspase activation in response to translational inhibition. 
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Mean + range of duplicates is shown. (d) HDSF sensitizes Vaco451 cells to translational 
inhibition. Mean +/− SD of triplicates is shown. (e) Didemnin B induces proteasome-
dependent Mcl-1 loss. Vaco451 cells were pre-treated with 10 μM MG132 for 30 minutes 
prior to the addition of either 10 μg/ml cycloheximide, 1 μM didemnin B, or DMSO for 3 
hours. Results are representative of two or more experiments. (f) Proteasome inhibition 
prevents didemnin B induced cell death. Mean +/− SEM of triplicates is shown. (g) 
Combinatorial inhibition of PPT1(12.5 μg/ml HDSF) and Mcl-1 (TW-37) selectively kills 
Vaco451 cells. Mean +/− SEM of triplicates is shown.
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Figure 4. A subset of breast, colon, and lung cancer cell lines are selectively sensitive to didemnin 
B
(a) The indicated cell lines were treated with didemnin B at the indicated concentrations for 
six hours before cell viability was measured. Mean +/− SEM of triplicates is shown. (b) The 
indicated cell lines were treated with 1 μM didemnin B or equivalent volume of DMSO for 
three hours. Caspase activity was measured using Caspase-Glo and expressed as fold-change 
vs. DMSO-treated cells. Mean + SEM of triplicates is shown. (c) The indicated cell lines 
were transfected with siRNA pools targeting LONRF1 (negative control), UBB (positive 
control), or PPT1 and Mcl-1. 72 hours later, cell viability was measured and normalized to 
control. Mean + SEM of triplicates is shown.
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Figure 5. Molecular response predictor for exceptional sensitivity to didemnin B
(a) Expression values of the indicated genes in the indicated cell lines are displayed as a 
heatmap. For compound sensitivity (top), a binary call was made with a value of “1” 
assigned to cell lines exhibiting sensitivity to didemnin B and a value of “0” assigned to 
resistant cell lines. Respective weights for each gene from the elastic net algorithm are 
displayed in yellow on the left. (b) The ranked predicted sensitivity for 1022 lines are 
displayed, with five experimentally tested cell lines indicated by name with dotted lines at 
the corresponding predicted sensitivity value. Cell lines are color-coded by anatomical site 
of origin in graph (left) and by rank (right). (c) The predicted sensitivities for 185 colorectal 
adenocarcinoma patients, computed using the elastic net-derived multi-feature biomarker 
from (a), are displayed in ranked order. (d) The indicated cell lines were treated with 1 μM 
didemnin B or equivalent volume of DMSO for six hours. Cell viability was measured using 
Cell TiterGlo, normalized to DMSO alone, and displayed as mean + SEM of n= 6–9 
replicates. (e) The indicated cell lines were treated with 1 μM didemnin B or equivalent 
volume DMSO for three hours. Caspase activity was measured using CaspaseGlo and 
displayed as fold-change versus DMSO-treated cells. Mean + SEM of triplicates are shown. 
In (d and e), * indicates P value < 0.05; ns indicates P value > 0.05.
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Figure 6. Predictive power in hematological cancer
(a) The normalized expression of the top 2% of genes differentially expressed between the 
sensitive and resistant class of cell lines, as determined by S2N analysis, is shown as a heat 
map. (b, c) the expression of two genes from (a), CLN5 (b), and EEF1A2 (c), in sensitive 
versus resistant cell lines is displayed. (d) Selective response of hematologic cell lines to 
didemnin B. The indicated cell lines were treated with didemnin B at the indicated 
concentrations for 24, 48, or 72 hours before cell viability was measured. Mean +/− range of 
duplicates is shown.
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